During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

During a live event, James W. Smithy, MD, MHS, and other oncologists discussed how their experience with immune-related ...

Nanobiotix S.A. Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients ...

Bristol Myers (BMY)’ treatment of small cell lung cancer, atigotatug plus nivolumab fixed dose combination, received FDA orphan designation, ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

The study enrolled 64 patients with treatment-naïve metastatic melanoma between March 2017 and July 2019. Participants ...

Treatment-related adverse events graded ≥ 3 occurred in 17% of patients assigned to nivolumab vs 6% randomized to placebo. Treatment-related events leading to discontinuation occurred in only 2% ...

A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a ...